Stock listing

BCBA:ABBVC AbbVie Inc. Acciones

Argentine listing (BCBA) of AbbVie Inc. · home listing NYSE:ABBV

Follow AbbVie Inc. into a list and get an email when it puts out news.

Home listing price · NYSE:ABBV

$285.42 USD +2.02 (+0.7%)

Close on Oct 16, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NYSE:ABBV

AbbVie Inc. logo
Ticker
BCBA:ABBVC
Asset type
Stock
Exchange
BCBA
Currency
USD

What changed lately

Calls

Upcoming

  • AbbVie (NYSE:ABBV) Q3 2026 Earnings Call

    Fri, Oct 30, 2026 · 9:00 AM ET

    Register

Replays

  • AbbVie (NYSE:ABBV) Q2 2026 Earnings Call

    Fri, Jul 31, 2026 · 9:00 AM ET

    Watch Transcript

  • AbbVie (NYSE:ABBV) Q1 2026 Earnings Call

    Wed, Apr 29, 2026 · 9:00 AM ET

    Watch Transcript

  • AbbVie (NYSE:ABBV) Q4 2025 Earnings Call

    Wed, Feb 04, 2026 · 9:00 AM ET

    Watch Transcript

Latest news

SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026

Oct 17, 2026

AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease

Oct 13, 2026

New SKYRIZI® (risankizumab-rzaa) and RINVOQ® (upadacitinib) Data Demonstrate Disease Control for Patients Living With Inflammatory Bowel Disease

Oct 11, 2026

AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma

Oct 5, 2026

AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo

Oct 1, 2026

AbbVie to Host Third-Quarter 2026 Earnings Conference Call

Oct 1, 2026

AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026

Sep 30, 2026

AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress

Sep 30, 2026

AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development

Sep 29, 2026

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

Sep 28, 2026

All AbbVie Inc. news

Decks

AbbVie Inc. on 6ix

News releases
135 in the last 12 months · 175 in all · newest Oct 17, 2026 · oldest 2025
Calls
31 calls with a replay · 31 with a transcript · latest Jul 31, 2026
Decks
21 decks · latest Jun 22, 2026

Where AbbVie Inc. is listed

ListingExchangeCountryCurrency
NYSE:ABBV · Home listingNYSEUnited StatesUSD
gettex:4ABgettexGermanyEUR
BCBA:ABBVBCBAArgentinaARS
SET:ABBV19SETThailandTHB
Tradegate:4ABTradegateGermanyEUR
TSX:ABBVTSXCanadaCAD
Xetra:4ABXetraGermanyEUR
Cboe Canada:ABBVCboe CanadaCanadaCAD
B3:ABBV34B3BrazilBRL
SET:ABBV80SETThailandTHB
LS Exchange:A1J84ELS ExchangeGermanyEUR
BMV:ABBVBMVMexicoMXN
Milan:1ABBVMilanItalyEUR
BCBA:ABBVDBCBAArgentinaUSD
LSIN:0QCVLSINUnited KingdomUSD
EUROTLX:4ABBVEUROTLXItalyEUR
Frankfurt:4ABFrankfurtGermanyEUR
Lang & Schwarz:A1J84ELang & SchwarzGermanyEUR
SIX Swiss:ABBVSIX SwissSwitzerlandCHF
Stuttgart:4ABStuttgartGermanyEUR
BIVA:ABBVBIVAMexicoMXN
BCBA:ABBVC · This pageBCBAArgentinaUSD
BOATS:ABBVBOATSUnited StatesUSD
VIE:ABBVViennaAustriaEUR
Munich:4ABMunichGermanyEUR
BCS:ABBVBCSChileUSD
Dusseldorf:4ABDusseldorfGermanyEUR
BX Swiss:4ABBX SwissSwitzerlandCHF
Hamburg:4ABHamburgGermanyEUR
BSESOF:4ABBSESOFBulgariaEUR
Dusseldorf:4AB0DusseldorfGermanyEUR
Frankfurt:4AB0FrankfurtGermanyEUR
SIX Swiss:ABBV.USDSIX SwissSwitzerlandUSD
BCS:ABBVCLBCSChileCLP
Turquoise:4ABDTurquoiseUnited KingdomEUR
BCBA:ABBV.CIBCBAArgentinaARS
Hanover:4ABHanoverGermanyEUR

Log in to ask 6ix AI your own questions about AbbVie Inc.